U.S. Stock News

CareDx (CDNA) shifted into profitability this quarter, backed by forecasts that call for robust annual earnings growth of about 80.2% and revenue growth of 11.1% per year for the next three years. The company’s $16.53 share price and Price-To-Earnings Ratio of 15.1x compare favorably to industry and peer averages. However, the recent results were buoyed by a significant, non-recurring gain of $89.4 million. With these headline numbers and a valuation still above the estimated fair value of...

Wolverine World Wide (WWW) has recently turned a profit, with its net profit margin improving over the past year. Earnings are forecast to grow an impressive 27.7% per year, outpacing the broader US market's 16% projection. The five-year annual earnings growth sits at 4.6%. With revenue expected to rise 7.1% per year going forward and the shares trading at $16.72, the company delivers high-quality earnings and maintains value metrics that stand out compared to peers. However, its financial...

EyePoint Pharmaceuticals (EYPT) remains unprofitable, with losses increasing at an annual rate of 25.2% over the past five years. While the company is forecast to stay in the red for at least three more years, revenue is projected to surge by 61.3% per year, outpacing the broader US market's expected 10.5% annual growth. Investors are weighing these robust revenue forecasts against ongoing share dilution and persistent unprofitability as they consider EyePoint’s current valuation. See our...

Weyco Group (WEYS) reported a net profit margin of 9.2% for the period, down from 10% last year, reflecting recent pressure on profitability. Despite this, the company stands out for its historically high earnings quality, with five-year annual earnings growth averaging a robust 31.5%. Its shares trade at $31.35, well below an estimated fair value of $90.59. Value-focused investors are likely to take note of its discounted price-to-earnings multiple and appealing dividend, although the latest...

Jones Lang LaSalle (JLL) posted annual revenue growth of 7.2%, trailing the broader US market’s 10.5% pace, while EPS is forecast to grow 15.3% per year, just under the US average of 16%. Over the past year, profit margins moved up from 1.8% to 2.3% and the company swung to positive earnings growth, up 47.4% after several years of decline. With high-quality earnings and valuation metrics below both peer and industry averages, these results could give investors reasons to view JLL’s latest...

Unity Software (U) remains in the red, with losses deepening by 10.8% per year over the past five years and no notable shift in profitability metrics. Revenue is forecast to grow at 10% annually, slightly lagging the broader US market's 10.5%. With shares trading at $42.36, well above the estimated fair value of $36.45 and a price-to-sales ratio of 10.1x that surpasses both peer and industry averages, investors see a company priced for growth but still searching for sustained profits in the...

agilon health (AGL) is expected to post revenue growth of 10.7% per year, slightly outpacing the broader US market’s 10.5% rate. The stock trades at $0.75 per share, which is significantly below its estimated fair value of $13.21 and reflects a substantial discount on key valuation metrics such as its 0.1x Price-to-Sales ratio. Despite this growth outlook, the company remains unprofitable and losses have been increasing by 7.9% annually over the past five years, which continues to put...

Navigator Holdings (NVGS) posted a net profit margin of 15.6%, edging up from 14.8% a year earlier, with earnings growth of 6.7% over the past year following a robust five-year average annual growth of 55.1%. While the company’s price-to-earnings ratio of 12.6x underscores its value orientation compared to US oil and gas peers, shares recently traded at $16.93 and sit above the internally estimated fair value of $2.68. Looking ahead, investors are weighing improved profitability and...

Chord Energy (CHRD) posted net profit margins of 5.3% for the twelve months leading up to September 30, 2025, down sharply from 22.2% a year earlier. This decline was largely driven by a one-off $578 million loss that weighed on earnings results for the period. Looking ahead, investors are weighing the short-term margin pressure and non-recurring losses against robust forward-looking projections. Annual earnings growth of 37.2% is expected and could outpace the broader US market. See our full...

MBIA (MBI) continues to operate at a loss, but over the last five years the company has narrowed those losses at an average annual rate of 3.2%. Despite this gradual progress, MBIA’s net profit margin is still in negative territory, and its valuation stands out. The Price-to-Sales Ratio sits at 3.5x, which is significantly higher than both the US insurance industry average of 1.1x and a peer group average of 1.3x. With profitability still out of reach and no fair value estimate available,...

Upstart Holdings (UPST) is forecast to grow earnings by 56.05% per year and increase revenue at an annual rate of 18.8%, outpacing the broader US market’s 10.5% growth projection. Despite the strong outlook, the company remains unprofitable, with losses having accelerated at 43.8% annually over the past five years. Investors will note the current Price-to-Sales ratio of 4.6x sits above industry and peer averages. With shares trading at $41.75, below analysts’ fair value estimate of $47.40,...

CeriBell (CBLL) is forecast to grow revenue by 23.39% per year, outpacing the US market’s projected 10.5% annual increase. Despite this trajectory, the company remains unprofitable and is not expected to reach profitability within the next three years, with no evidence of net profit margin improvement over the last twelve months. Investors are likely to weigh CeriBell's robust top-line expansion against continued losses and a valuation multiple well above peers. See our full analysis for...

Stoke Therapeutics (STOK) has moved into profitability over the past year and is now forecasting revenue growth of 20.1% per year, which handily outpaces the broader US market's 10.5% annual growth expectation. However, earnings are projected to decline by 5.6% each year over the next three years, suggesting the company's recently achieved profit status may be tested as the bottom line comes under pressure. The premium valuation and mixed outlook put investor attention squarely on how...

Arista Networks (ANET) posted net profit margins of 40.9%, up from 39% last year, and delivered a strong 32.1% earnings growth over the past year. Earnings are expected to grow 16.31% annually, with revenue projected to rise 16.6% per year. Both figures comfortably outpace the broader US market's revenue outlook of 10.5%. With five-year annualized earnings growth at 35.5%, investors will be weighing these rapid gains against a recent share price of $140.42, which is notably above the...

Corsair Gaming (CRSR) reported that losses have deepened at an average rate of 68.9% per year over the past five years, reflecting mounting unprofitability even as the company forecasts 8.7% annual revenue growth, which is below the 10.5% US market average. However, with earnings expected to grow at a robust 96.57% per year and profitability projected within the next three years, Corsair is seen by some investors as a turnaround candidate. See our full analysis for Corsair Gaming. Next up, we...

Solid Power (SLDP) continues to operate at a loss, with net losses deepening at a 50.3% annual rate over the last five years. Despite persistent negative profit margins, analysts forecast revenue growth of 40.5% per year, far outpacing the US market’s 10.5% average and SLDP’s peer group. This high growth outlook is very much in focus as investors weigh it against ongoing losses and a valuation that already sits far above sector averages. See our full analysis for Solid Power. Next, we’ll see...

Astera Labs (ALAB) has just turned profitable, with forecasts calling for earnings to grow at 27.1% per year and revenue to rise 23.5% annually, both comfortably ahead of US market averages. The company’s net profit margin has flipped from negative to positive, and its high quality earnings profile comes as shares are trading at a remarkable premium: a Price-To-Sales ratio of 49.9x, well above both direct semiconductor peers and the industry average. With no major risks or insider selling...

Andersons (ANDE) grew its earnings at an average annual rate of 16.2% over the past five years, recently posting a net profit margin of 0.7% compared to last year's 0.8%. Despite these longer-term gains, the company recorded negative earnings growth for the past year, creating a notable contrast with its historical trajectory. Investors are weighing the company’s profitable track record, slight margin compression, and the possibility that shares trading at $48.48, well below the estimated...

AnaptysBio (ANAB) is forecasting revenue growth of 25.9% per year, ahead of the broader US market’s 10.5% growth rate. Despite this, the company remains unprofitable, with losses climbing at an annual pace of 29.9% over the past five years. Net profit margins and earnings quality have yet to show improvement. Shares currently trade at a Price-to-Sales ratio of 8.2x, which offers better value than the US Biotech sector average of 10.3x, but appears expensive relative to peers at 5.8x. This...

Global Medical REIT (GMRE) has posted a turnaround, moving into profitability as net profit margins improved and earnings climbed by an average of 16.9% per year over the past five years. Looking ahead, earnings are forecast to accelerate by 22.6% per year, outpacing the broader US market's expected 16% growth. However, projected revenue growth of 2.9% per year lags market averages. A one-off gain of $6.8 million played a notable role in the latest results, so investors will want to keep an...

Summit Hotel Properties (INN) remains unprofitable, with net profit margins showing no improvement over the last year. Despite the lack of accelerated profit growth, the company has reduced its losses over the past five years at a steady annual rate of 66.5%. Revenue is forecast to rise by 2.1% each year, which trails well behind the broader US market’s 10.5% pace. For value-focused investors, shares trading at $5.27, well below the estimated fair value of $17.75, create an intriguing setup...

Rigel Pharmaceuticals (RIGL) has turned profitable in the last year, with net profits reversing after a string of losses. The company’s earnings grew at an impressive 40.2% per year over the past five years, signaling high quality performance. However, forward guidance calls for a 4% annual decline in earnings over the next three years and revenue growth of just 6.5% per year, falling short of the US market’s 10.5% average. Despite upbeat profit growth, the outlook now turns on whether Rigel...

Mosaic (MOS) delivered remarkable earnings growth of 284% over the last year, a sharp turnaround from its five-year average decline of -8.4% per year. Net profit margins strengthened significantly, moving from 2% to 8.4%. However, this surge was driven in part by a one-off $652.2 million gain, making some of these earnings non-recurring. Looking ahead, sentiment will weigh Mosaic’s low Price-to-Earnings Ratio of 8.9x and pricing below analyst fair value estimates against the forecast for...

Postal Realty Trust (PSTL) delivered a net profit margin of 10.4%, a substantial leap from last year’s 2.7%, as robust earnings fueled a 377.6% jump in growth over the past year. The company has built a five-year track record of consistent profitability gains and, looking forward, earnings are projected to grow at roughly 10% annually with revenue forecast to rise 11.5% per year, ahead of the general US market. Investors are weighing these strong margin improvements and sustained profit...